Dyne Therapeutics (DYN) Stock Price

Dyne Therapeutics Price

NYSE·CLOSED
16.09
​
Market closed

Revenue at Dyne Therapeutics has contracted by 16.6% per year over the past 10 years to 506.00 M USD. Earnings per share have grown at 6.4% per year over the last 10 years. For Dyne Therapeutics, the net margin of 15.0% is up versus -11,866.7% a few years ago. The consensus 12-month price target for Dyne Therapeutics is 38.00 USD, about 136.1% above where the stock trades today. Of 21 analysts, 18 rate the stock a buy — an overall Buy consensus.

Dyne Therapeutics stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Dyne Therapeutics business model & stock analysis

Dyne Therapeutics Inc. is a US biotechnology company specializing in the development of therapies for genetic muscle diseases (HMDs). The company was founded in 2018 and is headquartered in Waltham, Massachusetts.

Frequently asked questions about Dyne Therapeutics

The business model of Dyne Therapeutics Inc revolves around developing life-transforming therapies for patients with serious muscle diseases. By harnessing their proprietary force-based platform, Dyne Therapeutics aims to overcome the limitations of traditional approaches and enable the delivery of nucleic acids, such as oligonucleotides, to muscle tissues. This innovative approach holds the potential to address a wide range of muscle diseases. Dyne Therapeutics Inc is dedicated to pushing the boundaries of science and leveraging its expertise to create impactful treatments for patients in need.

Dyne Therapeutics Inc is primarily active in the biotechnology industry.

The main competitors of Dyne Therapeutics Inc in the market include companies such as Sarepta Therapeutics, Wave Life Sciences, and Solid Biosciences.

Dyne Therapeutics Inc is a leading biotechnology company that specializes in developing innovative therapies for patients suffering from muscle diseases. Established in [year], Dyne Therapeutics has rapidly grown to become a prominent player in the field. The company's dedicated team of experts combines their extensive knowledge of muscle biology with advanced technologies to create transformative treatments. Dyne Therapeutics focuses on developing targeted therapies that aim to restore muscle function and improve patients' quality of life. With a strong commitment to research and development, Dyne Therapeutics is dedicated to making a meaningful impact on the lives of individuals living with muscle diseases.

As of October 2021, Dyne Therapeutics Inc has achieved significant milestones. The company successfully completed its initial public offering (IPO) in May 2020, raising approximately $201 million. Dyne Therapeutics also established strategic collaborations with leading organizations like Roche, Novartis, Sanofi, and Sarepta Therapeutics. They have made remarkable progress in their research and development efforts, with a focus on advancing their proprietary FORCE platform for treating muscle diseases. Dyne Therapeutics has received notable recognition for its innovative approach and has attracted investment from prominent venture capital firms. The company continues to make strides towards developing novel therapies for patients with serious muscle disorders.

Dyne Therapeutics Inc is primarily present in the United States.

Dyne Therapeutics Inc represents a set of core values and corporate philosophy that sets it apart in the industry. The company prioritizes innovation, excellence, and patient-centricity in all aspects of its operations. Dyne Therapeutics is committed to developing life-changing therapies using its proprietary FORCE™ platform to treat serious muscle diseases. With an unwavering dedication to scientific rigor and collaboration, Dyne Therapeutics aims to redefine the treatment landscape for patients in need. By combining cutting-edge technology with a focus on patient outcomes, Dyne Therapeutics strives to make a meaningful impact in the lives of people affected by muscle diseases.

Analysts currently set an average price target of 38.00 USD for the Dyne Therapeutics stock (median: 38.00 USD), implying +136.1 % versus the latest price. The consensus is based on 21 analyst ratings.

21 analysts currently rate the Dyne Therapeutics stock: 18 recommend buying, 2 holding and 1 selling.

Converted at the current exchange rate, the Dyne Therapeutics share trades at 14.67 EUR (16.09 USD).

The Dyne Therapeutics share (DYN) is listed on 2 stock exchanges, including: NYSE (DYN).

Dyne Therapeutics is a biotechnology company specializing in the development of new therapies for inherited muscular diseases. The company is based in Waltham, Massachusetts, USA. They focus on researching, developing, and marketing innovative therapies for diseases caused by genetic defects. One of their main areas of focus is the development of antisense oligonucleotides (ASOs), which are short nucleotide sequences that can target specific RNA molecules and influence gene expression. They have also developed a proprietary ASO technology platform that allows them to deliver ASOs to specific tissues and cells relevant to certain genetic diseases. They are developing therapeutics for Duchenne muscular dystrophy (DMD) and other inherited muscular diseases. They are also developing therapies aimed at stabilizing and increasing the production of important structural and functional proteins. An example of this is their innovative drug, Dyn101, which aims to replace or enhance the missing protein in DMD patients. The company's products are still in the development phase and are not currently commercially available. They are working on a patented ASO technology platform and have several promising drug candidates in clinical development stages. They use both internal research and development as well as external partnerships to expand their therapy options. They collaborate with renowned research institutions and universities to discover innovative new therapies and technologies and validate their clinical efficacy and safety. Their business model is focused on long-term growth and success. They are dedicated to developing innovative therapies for inherited muscular diseases and expect to achieve positive clinical results in the coming years, which will allow them to apply for therapeutic approval. In summary, Dyne Therapeutics is a biotechnology company specialized in developing therapeutics based on antisense oligonucleotides and other innovative technologies to treat inherited muscular diseases. They aim to better meet the needs of patients affected by these diseases and establish themselves as a leading company in this field through continuous research and development of new products and technologies.

The revenue cannot currently be calculated for Dyne Therapeutics.

The expected profit of Dyne Therapeutics is -630.69 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Dyne Therapeutics is currently -3.28. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Dyne Therapeutics stock.

The P/S cannot be calculated for Dyne Therapeutics currently.

The Eulerpool Quality Score for Dyne Therapeutics is 2/10.

The ISIN of Dyne Therapeutics is US26818M1080. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Dyne Therapeutics is A2QB6B. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Dyne Therapeutics is DYN. The ticker symbol is used to trade Dyne Therapeutics shares on the stock exchange.

Fair ValueTerminal
14.65 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website dyne-tx.com
Currency
USD
Initial public offering
Sep 17, 2020
ISIN
US26818M1080
Cusip
26818M108
Sedol
BN15WD1
Market capitalization
2.60 B USDMid Cap
52-Week Range
PEG
0.11
P/E ratio
P/Ee 2026
-3.28
P/Ee 2027
-3.62
P/Ee 2028
-4.24
P/Ee 2029
-6.64
P/Ee 2030
-44.97
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
2.68
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-44.96 %
Last updated Nov 19, 2026, 7:11 PM

Dyne Therapeutics Ticker

NASDAQ · DYNNEW YORK · DYN

Dyne Therapeutics FIGI

DYN:US · BBG00NSGPJD0DYN:UA · BBG00WYHNJX1DYN:UC · BBG00WYHNJY0DYN:UN · BBG00WYHNK04DYN:UP · BBG00WYHNK13DYN:UB · BBG00WYHNK31DYN:UM · BBG00WYHNK59DYN:UX · BBG00WYHNK68DYN:UD · BBG00WYHNKC1DYN:UW · BBG00WYHNKF8DYN:UF · BBG00WYHNKG7DYN:VY · BBG00WYHNKH6